Following years of subdued activity, the SPAC market has rebounded in 2025. Established sponsors are driving new blank check issuance to a four-year high, and now two notable mergers have bucked the trend of high redemptions to raise more than $100 million...read more
There are no companies scheduled for the holiday week ahead, and we likely won’t see any more IPOs until 2020.
Lock-up periods will be expiring for seven companies. On Monday, December 23: Cambium Networks (CMBM). On Tuesday, December 24: ...read more
Eight companies raised $2.1 billion this past week, capping off the US IPO market's largest quarter in five years. The week was split between tech and biotechs, including two in the biotech space that went public at valuations of more than $2.0 billion. Over 10 ...read more
BridgeBio Pharma, a late-stage biotech developing therapies for genetic diseases and cancers, raised $349 million by offering 20.5 million shares at $17, above the range of $14 to $16. The company previously filed to offer 20.0 million shares, after first...read more
Two de-SPACs defy trends to raise $100 million with low redemptions
Following years of subdued activity, the SPAC market has rebounded in 2025. Established sponsors are driving new blank check issuance to a four-year high, and now two notable mergers have bucked the trend of high redemptions to raise more than $100 million...read more
US IPO Week Ahead: The IPO market takes its holiday vacation
There are no companies scheduled for the holiday week ahead, and we likely won’t see any more IPOs until 2020. Lock-up periods will be expiring for seven companies. On Monday, December 23: Cambium Networks (CMBM). On Tuesday, December 24: ...read more
US IPO Weekly Recap: Big biotechs score big as Adaptive soars 142%
Eight companies raised $2.1 billion this past week, capping off the US IPO market's largest quarter in five years. The week was split between tech and biotechs, including two in the biotech space that went public at valuations of more than $2.0 billion. Over 10 ...read more
BridgeBio Pharma prices upsized IPO above the range at $17 in year's largest biotech IPO
BridgeBio Pharma, a late-stage biotech developing therapies for genetic diseases and cancers, raised $349 million by offering 20.5 million shares at $17, above the range of $14 to $16. The company previously filed to offer 20.0 million shares, after first...read more